Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Payables (2016 - 2025)

Historic Payables for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $44.0 million.

  • Outlook Therapeutics' Payables rose 242.66% to $44.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $44.0 million, marking a year-over-year increase of 242.66%. This contributed to the annual value of $40.1 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Outlook Therapeutics' Payables is $44.0 million, which was up 242.66% from $40.1 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Payables ranged from a high of $44.0 million in Q4 2025 and a low of $19.8 million during Q1 2025